Patents by Inventor Jochen G. Salfeld
Jochen G. Salfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140286941Abstract: Methods of treating TNF?-related disorders comprising administering TNF? inhibitors, including TNF? antibodies are described.Type: ApplicationFiled: May 2, 2014Publication date: September 25, 2014Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff
-
Publication number: 20140286940Abstract: Methods of treating TNF?-related disorders comprising administering TNF? inhibitors, including TNF? antibodies are described.Type: ApplicationFiled: May 2, 2014Publication date: September 25, 2014Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff
-
Publication number: 20140286939Abstract: Methods of treating TNF?-related disorders comprising administering TNF? inhibitors, including TNF? antibodies are described.Type: ApplicationFiled: May 2, 2014Publication date: September 25, 2014Applicant: AbbVie Biotechnology, Ltd.Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff
-
Publication number: 20140213768Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.Type: ApplicationFiled: September 10, 2013Publication date: July 31, 2014Applicant: ABBVIE INC.Inventors: Chengbin WU, Tariq GHAYUR, Richard W. DIXON, Jochen G. SALFELD
-
Patent number: 8765918Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: March 23, 2012Date of Patent: July 1, 2014Assignee: Abbott GmbH & Co., KGInventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
-
Patent number: 8753633Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: June 15, 2012Date of Patent: June 17, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R. J. M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20140154256Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.Type: ApplicationFiled: February 10, 2014Publication date: June 5, 2014Applicant: AbbVie, Inc.Inventors: Chengbin Wu, Tariq Ghayur, Richard W. Dixon, Jochen G. Salfeld
-
Patent number: 8722855Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: October 28, 2010Date of Patent: May 13, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
-
Publication number: 20140100359Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.Type: ApplicationFiled: September 10, 2013Publication date: April 10, 2014Applicant: ABBVIE INC.Inventors: Chengbin WU, Tariq GHAYUR, Richard W. DIXON, Jochen G. SALFELD
-
Publication number: 20130330356Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: August 12, 2013Publication date: December 12, 2013Applicant: ABBVIE BIOTECHNOLOGY LTD.Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R.J.M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20130330357Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: August 12, 2013Publication date: December 12, 2013Applicant: ABBVIE BIOTECHNOLOGY LTDInventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R.J.M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20130243763Abstract: Methods of treating TNF?-related disorders comprising administering TNF? inhibitors, including TNF? antibodies are described.Type: ApplicationFiled: May 28, 2013Publication date: September 19, 2013Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot Keith Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff
-
Publication number: 20130243786Abstract: Methods of treating TNF?-related disorders comprising administering TNF? inhibitors, including TNF? antibodies are described.Type: ApplicationFiled: July 18, 2003Publication date: September 19, 2013Applicant: Abbott Biotechnology Ltd.Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel Edward Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven Fischkoff
-
Publication number: 20130243789Abstract: Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins.Type: ApplicationFiled: January 11, 2013Publication date: September 19, 2013Applicant: Abbott LaboratoriesInventors: Gerald R. Carson, Jochen G. Salfeld, Dean A. Regier, Jijie Gu, Wendy Gion, Yune Z. Kunes
-
Publication number: 20130115224Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: January 8, 2013Publication date: May 9, 2013Inventors: Jochen G. SALFELD, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R.j.m. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 8414894Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: December 30, 2011Date of Patent: April 9, 2013Assignee: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, John A. Mankovich, Deborah J. Allen, Hendricus R.J.M. Hoogenboom, Boris Labkovsky, Brian T. McGuinness, Paul Sakorafas, Michael White, Alison J. Wilton, Zehra Kaymakcalan, Andrew J. Roberts, David Schoenhaut, Tristan J. Vaughan
-
Patent number: 8372401Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: May 8, 2012Date of Patent: February 12, 2013Assignee: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 8372400Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: October 13, 2009Date of Patent: February 12, 2013Assignee: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R. J. M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Publication number: 20130004416Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.Type: ApplicationFiled: August 31, 2012Publication date: January 3, 2013Applicant: Abbott LaboratoriesInventors: Chengbin WU, Tariq Ghayur, Richard W. Dixon, Jochen G. Salfeld
-
Publication number: 20120258114Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: June 15, 2012Publication date: October 11, 2012Inventors: JOCHEN G. SALFELD, DEBORAH J. ALLEN, HENDRICUS R.J.M. HOOGENBOOM, ZEHRA KAYMACALAN, BORIS LABKOVSKY, JOHN A. MANKOVICH, BRIAN T. MCGUINNESS, ANDREW J. ROBERTS, PAUL SAKORAFAS, DAVID SCHOENHAUT, TRISTAN J. VAUGHAN, MICHAEL WHITE, ALISON J. WILTON